Title | Creator | Date | ||
---|---|---|---|---|
1 | Sharp Edge Eye Syndrome: A Case Report and Survey of Self-Identified Individuals | Merrick S. Reynolds; Bradley J. Katz; Kathleen B. Digre; Ben J. Brintz; Lenora M. Olson; Judith E. A. Warner | 2022-12 | |
2 | The Impact of Leber Hereditary Optic Neuropathy on the Quality of Life of Patients and Their Relatives: A Qualitative Study | Benson S. Chen; Erik Holzinger; Magali Taiel; Patrick Yu-Wai-Man | 2022-09 | |
3 | Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach | Raymond S. Douglas; Andrea L. Kossler; Jody Abrams; Cesar A. Briceño; David Gay; Andrew Harrison; Michael Lee; John Nguyen; Shannon S. Joseph; Dianne Schlachter; Jeremy Tan; Judah Lynch; Louisa Oliver; Richard Perry; Shoaib Ugradar | 2022-09 | |
4 | Impact of Greater Occipital Nerve Block on Photophobia Levels in Migraine Patients | Javier A Membrilla; Íñigo de Lorenzo; Lucía Sánchez-Casado; María Sastre; Javier Díaz de Terán | 2022-09 | |
5 | Rehabilitation of Visual Loss: Where We Are and Where We Need to Be | Behzad Mansouri, MD, PhD, FRCPC; Marinya Roznik, Bsc; Joseph F. Rizzo III, MD; Sashank Prasad, MD | 2018-06 | |
6 | More Than Meets the Eye: The Eye and Migraine -- What You Need to Know | Kathleen B. Digre, MD | 2018-06 | |
7 | Safety and Tolerability of Acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial | Martin W. ten Hove, MD; Deborah I. Friedman, MD; Anil D. Patel, MD; Isabella Irrcher, PhD; Michael Wall, MD; Michael P. McDermott, PhD; for the NORDIC Idiopathic Intracranial Hypertension Study Group | 2016-03 | |
8 | Factors Affecting Visual Field Outcomes in the Idiopathic Intracranial Hypertension Treatment Trial | Kimberly E. Cello, BS; John L. Keltner, MD; Chris A. Johnson, PhD; Michael Wall, MD for the NORDIC Idiopathic Intracranial Hypertension Study Group | 2016-03 |